Related Experiment Video
Updated: Aug 11, 2026
06:13
Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
Published on: February 21, 2020
Non-imidazole histamine NO-donor H3-antagonists
Paolo Tosco1, Massimo Bertinaria, Antonella Di Stilo
1Dipartimento di Scienza e Tecnologia del Farmaco, Via P. Giuria 9, I-10125 Torino, Italy.
Farmaco (Societa Chimica Italiana : 1989)
|June 2, 2005
Summary
Researchers synthesized novel H3-antagonist compounds by replacing the imidazole ring with a piperazino moiety. This modification generally reduced H3-antagonist activity and introduced new pharmacological effects, likely via other receptor interactions.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Discovery
Background:
- Development of H3-antagonists is crucial for treating neurological disorders.
- Previous research focused on furoxan and furazan derivatives of Imoproxifan.
- Non-imidazole H3-ligands like A-923 offer alternative structural scaffolds.
Purpose of the Study:
- To synthesize and characterize novel H3-antagonist compounds.
- To investigate the impact of replacing the imidazole ring with an ethoxycarbonylpiperazino moiety.
- To evaluate the pharmacological activity and receptor affinity of the new chemical entities.
Main Methods:
- Chemical synthesis of novel compound series.
- Pharmacological characterization, including H3-antagonist activity assessment.
- Determination of hydrophilic-lipophilic balance (HLB).
Main Results:
- Synthesis of a new series of H3-antagonist analogues was successful.
- Imidazole ring replacement generally led to decreased H3-antagonist activity compared to parent compounds.
- Some derivatives exhibited relaxing effects on guinea-pig ileum, suggesting off-target receptor interactions.
Conclusions:
- The ethoxycarbonylpiperazino moiety can modulate H3-antagonist properties.
- Structural modifications impact receptor binding profiles and introduce novel pharmacological activities.
- Further research is warranted to explore the potential of these compounds and their off-target effects.
Related Concept Videos
01:30Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:15Upper Respiratory Drugs: First and Second-Generation Antihistamines
Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...